First leishmaniasis vaccine to enter Phase 1 clinical trial, Ohio State announces

Ohio State University announced the start of a Phase 1 clinical trial. The trial will evaluate the first vaccine candidate targeting leishmaniasis. Leishmaniasis is a parasitic disease affecting millions worldwide. The study will assess safety and immune response in human volunteers. Researchers aim to generate data that could advance vaccine development. The trial marks a milestone in efforts to prevent the disease. Funding and collaboration details were noted by Ohio State News. Successful results could pave the way for later‑stage trials.